Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson's disease to inform clinical trial designs.

Ahamadi M, Conrado DJ, Macha S, Sinha V, Stone J, Burton J, Nicholas T, Gallagher J, Dexter D, Bani M, Boroojerdi B, Smit H, Weidemann J, Chen C, Yang M, Maciuca R, Lawson R, Burn D, Marek K, Venuto C, Stafford B, Akalu M, Stephenson D, Romero K; Critical Path for Parkinson's (CPP) Consortium.

Clin Pharmacol Ther. 2019 Sep 23. doi: 10.1002/cpt.1634. [Epub ahead of print]

PMID:
31544231
2.

Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.

Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S.

J Neurol. 2019 Aug;266(8):1927-1936. doi: 10.1007/s00415-019-09348-3. Epub 2019 May 9.

3.

Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.

Isaacson SH, Boroojerdi B, Waln O, McGraw M, Kreitzman DL, Klos K, Revilla FJ, Heldman D, Phillips M, Terricabras D, Markowitz M, Woltering F, Carson S, Truong D.

Parkinsonism Relat Disord. 2019 Jul;64:132-137. doi: 10.1016/j.parkreldis.2019.01.025. Epub 2019 Jan 28.

PMID:
30948242
4.

Clinical feasibility of a wearable, conformable sensor patch to monitor motor symptoms in Parkinson's disease.

Boroojerdi B, Ghaffari R, Mahadevan N, Markowitz M, Melton K, Morey B, Otoul C, Patel S, Phillips J, Sen-Gupta E, Stumpp O, Tatla D, Terricabras D, Claes K, Wright JA Jr, Sheth N.

Parkinsonism Relat Disord. 2019 Apr;61:70-76. doi: 10.1016/j.parkreldis.2018.11.024. Epub 2018 Nov 27.

PMID:
30635244
5.

Impact of motor fluctuations on real-life gait in Parkinson's patients.

Silva de Lima AL, Evers LJW, Hahn T, de Vries NM, Daeschler M, Boroojerdi B, Terricabras D, Little MA, Bloem BR, Faber MJ.

Gait Posture. 2018 May;62:388-394. doi: 10.1016/j.gaitpost.2018.03.045. Epub 2018 Mar 28.

PMID:
29627498
6.

Feasibility of large-scale deployment of multiple wearable sensors in Parkinson's disease.

Silva de Lima AL, Hahn T, Evers LJW, de Vries NM, Cohen E, Afek M, Bataille L, Daeschler M, Claes K, Boroojerdi B, Terricabras D, Little MA, Baldus H, Bloem BR, Faber MJ.

PLoS One. 2017 Dec 20;12(12):e0189161. doi: 10.1371/journal.pone.0189161. eCollection 2017.

7.

Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.

Chung SJ, Asgharnejad M, Bauer L, Benitez A, Boroojerdi B, Heidbrede T, Little A, Kim HJ.

Expert Rev Neurother. 2017 Jul;17(7):737-749. doi: 10.1080/14737175.2017.1336087. Review.

PMID:
28548894
8.

Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis.

Antonini A, Chaudhuri KR, Boroojerdi B, Asgharnejad M, Bauer L, Grieger F, Weintraub D.

Eur J Neurol. 2016 Oct;23(10):1556-65. doi: 10.1111/ene.13078. Epub 2016 Jul 18.

9.

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.

Giladi N, Asgharnejad M, Bauer L, Grieger F, Boroojerdi B.

J Parkinsons Dis. 2016 Apr 2;6(2):401-11. doi: 10.3233/JPD-150758.

10.

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.

LeWitt PA, Poewe W, Elmer LW, Asgharnejad M, Boroojerdi B, Grieger F, Bauer L.

Clin Neuropharmacol. 2016 Mar-Apr;39(2):88-93. doi: 10.1097/WNF.0000000000000133.

11.

Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.

Timmermann L, Asgharnejad M, Boroojerdi B, Dohin E, Woltering F, Elmer LW.

Expert Opin Pharmacother. 2015;16(10):1423-33. doi: 10.1517/14656566.2015.1049597. Epub 2015 May 22.

PMID:
25997442
12.

Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.

Giladi N, Ghys L, Surmann E, Boroojerdi B, Jankovic J.

Parkinsonism Relat Disord. 2014 Dec;20(12):1345-51. doi: 10.1016/j.parkreldis.2014.09.016. Epub 2014 Sep 28.

PMID:
25444083
13.

Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study.

Kassubek J, Chaudhuri KR, Zesiewicz T, Surmann E, Boroojerdi B, Moran K, Ghys L, Trenkwalder C.

BMC Neurol. 2014 Mar 6;14:42. doi: 10.1186/1471-2377-14-42.

14.

Associations between severity of motor function and nonmotor symptoms in Parkinson's disease: a post hoc analysis of the RECOVER Study.

Swick TJ, Friedman JH, Chaudhuri KR, Surmann E, Boroojerdi B, Moran K, Ghys L, Trenkwalder C.

Eur Neurol. 2014;71(3-4):140-7. doi: 10.1159/000355019. Epub 2014 Jan 21.

PMID:
24457253
15.

The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.

Giladi N, Boroojerdi B, Surmann E.

J Neural Transm (Vienna). 2013 Sep;120(9):1321-9. doi: 10.1007/s00702-013-1001-5. Epub 2013 Mar 19.

PMID:
23508526
16.

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.

LeWitt PA, Boroojerdi B, Surmann E, Poewe W; SP716 Study Group; SP715 Study Group.

J Neural Transm (Vienna). 2013 Jul;120(7):1069-81. doi: 10.1007/s00702-012-0925-5. Epub 2012 Dec 4.

17.

Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability.

Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B.

Parkinsonism Relat Disord. 2013 Jan;19(1):37-42. doi: 10.1016/j.parkreldis.2012.06.009. Epub 2012 Sep 3.

PMID:
22954721
18.

Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.

Streffer JR, Grachev ID, Fitzer-Attas C, Gomez-Mancilla B, Boroojerdi B, Bronzova J, Ostrowitzki S, Victor SJ, Fontoura P, Alexander R.

Mov Disord. 2012 Apr 15;27(5):651-5. doi: 10.1002/mds.25017. Review.

PMID:
22508283
19.

Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.

Elmer LW, Surmann E, Boroojerdi B, Jankovic J.

Parkinsonism Relat Disord. 2012 Jun;18(5):488-93. doi: 10.1016/j.parkreldis.2012.01.008. Epub 2012 Feb 10.

PMID:
22326237
20.

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease.

Kim HJ, Jeon BS, Lee WY, Lee MC, Kim JW, Kim JM, Ahn TB, Cho J, Chung SJ, Grieger F, Whitesides J, Boroojerdi B.

BMC Neurol. 2011 Aug 10;11:100. doi: 10.1186/1471-2377-11-100.

21.

Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline.

Ghys L, Surmann E, Whitesides J, Boroojerdi B.

Expert Opin Pharmacother. 2011 Sep;12(13):1985-98. doi: 10.1517/14656566.2011.604031. Epub 2011 Jul 27.

PMID:
21790503
22.

Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).

Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR; Recover Study Group.

Mov Disord. 2011 Jan;26(1):90-9. doi: 10.1002/mds.23441. Epub 2010 Nov 18.

23.

Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease.

Giladi N, Fichtner A, Poewe W, Boroojerdi B.

J Neural Transm (Vienna). 2010 Dec;117(12):1395-9. doi: 10.1007/s00702-010-0506-4. Epub 2010 Nov 16.

PMID:
21080009
24.

Cortical activation by Yamamoto new scalp acupuncture in the treatment of patients with a stroke: a sham-controlled study using functional MRI.

Schockert T, Schnitker R, Boroojerdi B, Smith IQ, Yamamoto T, Vietzke K, Kastrau F.

Acupunct Med. 2010 Dec;28(4):212-4. doi: 10.1136/aim.2010.002683. Epub 2010 Oct 5. No abstract available.

PMID:
20923941
25.

Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.

Boroojerdi B, Wolff HM, Braun M, Scheller DK.

Drugs Today (Barc). 2010 Jul;46(7):483-505. doi: 10.1358/dot.2010.46.7.1463530. Review.

PMID:
20683503
26.

Transdermal rotigotine for the perioperative management of Parkinson's disease.

Wüllner U, Kassubek J, Odin P, Schwarz M, Naumann M, Häck HJ, Boroojerdi B, Reichmann H; NEUPOS Study Group.

J Neural Transm (Vienna). 2010 Jul;117(7):855-9. doi: 10.1007/s00702-010-0425-4. Epub 2010 Jun 10.

27.

High doses of rotigotine transdermal patch: results of an open-label, dose-escalation trial in patients with advanced-stage, idiopathic Parkinson disease.

Rektor I, Babic T, Boothmann B, Polivka J, Boroojerdi B, Randerath O.

Clin Neuropharmacol. 2009 Jul-Aug;32(4):193-8. doi: 10.1097/WNF.0b013e31819a689f.

PMID:
19644228
28.

The dorsal premotor cortex orchestrates concurrent speech and fingertapping movements.

Meister IG, Buelte D, Staedtgen M, Boroojerdi B, Sparing R.

Eur J Neurosci. 2009 May;29(10):2074-82. doi: 10.1111/j.1460-9568.2009.06729.x. Epub 2009 May 9.

PMID:
19453637
29.

The role of the anterior intraparietal sulcus in crossmodal processing of object features in humans: an rTMS study.

Buelte D, Meister IG, Staedtgen M, Dambeck N, Sparing R, Grefkes C, Boroojerdi B.

Brain Res. 2008 Jun 27;1217:110-8. doi: 10.1016/j.brainres.2008.03.075. Epub 2008 Apr 9.

PMID:
18501339
30.

Treatment of juvenile stroke using Yamamoto New Scalp Acupuncture (YNSA) - a case report.

Yamamoto T, Schockert T, Boroojerdi B.

Acupunct Med. 2007 Dec;25(4):200-2.

PMID:
18160931
31.

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.

Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH; SP513 investigators.

Mov Disord. 2007 Dec;22(16):2398-404.

PMID:
17935234
32.

Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.

LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J.

Clin Neuropharmacol. 2007 Sep-Oct;30(5):256-65.

PMID:
17909303
33.

A repetition suppression effect lasting several days within the semantic network.

Meister IG, Buelte D, Sparing R, Boroojerdi B.

Exp Brain Res. 2007 Nov;183(3):371-6. Epub 2007 Jul 19.

PMID:
17634931
34.

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.

Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators.

Lancet Neurol. 2007 Jun;6(6):513-20.

PMID:
17509486
35.

Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.

Jankovic J, Watts RL, Martin W, Boroojerdi B.

Arch Neurol. 2007 May;64(5):676-82.

PMID:
17502466
36.
37.

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.

Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J.

Neurology. 2007 Jan 23;68(4):272-6. Epub 2007 Jan 3. Erratum in: Neurology. 2007 Aug 7;69(6):617. Neurology. 2007 Dec 4;69(23):2187.

PMID:
17202432
38.

Rotigotine transdermal system for perioperative administration.

Korczyn AD, Reichmann H, Boroojerdi B, Häck HJ.

J Neural Transm (Vienna). 2007 Feb;114(2):219-21. Epub 2006 Dec 21.

PMID:
17177076
39.

Hemiextinction induced by transcranial magnetic stimulation over the right temporo-parietal junction.

Meister IG, Wienemann M, Buelte D, Grünewald C, Sparing R, Dambeck N, Boroojerdi B.

Neuroscience. 2006 Sep 29;142(1):119-23. Epub 2006 Jul 28.

PMID:
16876326
40.

Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study.

Babic T, Boothmann B, Polivka J, Rektor I, Boroojerdi B, Häck HJ, Randerath O.

Clin Neuropharmacol. 2006 Jul-Aug;29(4):238-42.

PMID:
16855426
41.

Functional connectivity between cortical hand motor and language areas during recovery from aphasia.

Meister IG, Sparing R, Foltys H, Gebert D, Huber W, Töpper R, Boroojerdi B.

J Neurol Sci. 2006 Sep 25;247(2):165-8. Epub 2006 Jun 5.

PMID:
16737714
42.

Interhemispheric imbalance during visuospatial attention investigated by unilateral and bilateral TMS over human parietal cortices.

Dambeck N, Sparing R, Meister IG, Wienemann M, Weidemann J, Topper R, Boroojerdi B.

Brain Res. 2006 Feb 9;1072(1):194-9. Epub 2006 Jan 19.

PMID:
16426588
43.

Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.

Güldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B.

Clin Neuropharmacol. 2005 May-Jun;28(3):106-10.

PMID:
15965307
44.

Investigation of the primary visual cortex using short-interval paired-pulse transcranial magnetic stimulation (TMS).

Sparing R, Dambeck N, Stock K, Meister IG, Huetter D, Boroojerdi B.

Neurosci Lett. 2005 Jul 15;382(3):312-6. Epub 2005 Apr 14.

PMID:
15925110
45.

Effects of long-term practice and task complexity in musicians and nonmusicians performing simple and complex motor tasks: implications for cortical motor organization.

Meister I, Krings T, Foltys H, Boroojerdi B, Müller M, Töpper R, Thron A.

Hum Brain Mapp. 2005 Jul;25(3):345-52.

PMID:
15852385
46.

The neural correlate of very-long-term picture priming.

Meister IG, Weidemann J, Foltys H, Brand H, Willmes K, Krings T, Thron A, Töpper R, Boroojerdi B.

Eur J Neurosci. 2005 Feb;21(4):1101-6.

PMID:
15787715
47.

Task-dependent intracortical inhibition is impaired in focal hand dystonia.

Bütefisch CM, Boroojerdi B, Chen R, Battaglia F, Hallett M.

Mov Disord. 2005 May;20(5):545-51.

48.

Shift in sound localization induced by rTMS of the posterior parietal lobe.

Lewald J, Wienemann M, Boroojerdi B.

Neuropsychologia. 2004;42(12):1598-607.

PMID:
15327928
49.

Playing piano in the mind--an fMRI study on music imagery and performance in pianists.

Meister IG, Krings T, Foltys H, Boroojerdi B, Müller M, Töpper R, Thron A.

Brain Res Cogn Brain Res. 2004 May;19(3):219-28.

PMID:
15062860
50.

Neural correlates of phosphene perception.

Meister IG, Weidemann J, Dambeck N, Foltys H, Sparing R, Krings T, Thron A, Boroojerdi B.

Suppl Clin Neurophysiol. 2003;56:305-11. No abstract available.

PMID:
14677407

Supplemental Content

Loading ...
Support Center